Sanofi SA (EPA:SAN) has been assigned a €85.00 ($101.19) price target by research analysts at BNP Paribas in a research note issued on Tuesday. The firm currently has a “neutral” rating on the stock.
Several other research firms have also recently commented on SAN. Kepler Capital Markets set a €89.00 ($105.95) target price on Sanofi SA and gave the company a “buy” rating in a research note on Wednesday, July 26th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi SA in a research note on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Credit Suisse Group set a €95.00 ($113.10) target price on Sanofi SA and gave the company a “buy” rating in a research note on Tuesday, July 4th. Finally, Jefferies Group LLC set a €90.00 ($107.14) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Friday, June 16th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. Sanofi SA presently has an average rating of “Hold” and an average target price of €88.19 ($104.99).
Sanofi SA (SAN) opened at 81.40 on Tuesday. The company has a market cap of €102.22 billion and a price-to-earnings ratio of 11.36. The company’s 50-day moving average is €25.48 and its 200 day moving average is €25.74. Sanofi SA has a 12 month low of €62.50 and a 12 month high of €92.97.
WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/sanofi-sa-san-given-a-85-00-price-target-at-bnp-paribas.html.
About Sanofi SA
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.